Innoviva, Inc.
(NASDAQ : INVA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SHPGShire PLC Sponsored ADR
-3.02%172.750.4%$312.80m
AMRNAmarin Corporation Plc Sponsored ADR
-6.00%16.912.0%$244.81m
JAZZJazz Pharmaceuticals Plc
-1.62%141.172.2%$120.91m
PRGOPerrigo Co. Plc
-4.30%59.936.8%$105.96m
GWPHGW Pharmaceuticals PLC Sponsored ADR
1.73%124.846.3%$61.48m
MNKMallinckrodt Plc
-3.62%20.7521.1%$55.15m
ENDPEndo International Plc
-0.26%11.578.9%$50.42m
ICLRICON Plc
-1.64%139.634.1%$44.84m
HZNPHorizon Pharma plc
-2.04%19.657.4%$42.45m
UTHRUnited Therapeutics Corporation
-2.95%109.4414.4%$40.43m
SAGESAGE Therapeutics, Inc.
-3.02%102.689.6%$39.65m
ICPTIntercept Pharmaceuticals, Inc.
-4.26%102.2618.6%$38.77m
CTLTCatalent Inc
-2.68%36.312.4%$37.78m
PTLAPortola Pharmaceuticals, Inc.
0.73%20.687.7%$32.06m
ZGNXZogenix, Inc.
-2.43%42.5510.0%$25.36m

Company Profile

Innoviva, Inc. engages in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Brisbane, CA.